{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:06:20Z","timestamp":1792886780510,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and is a major contributor to the global burden of chronic kidney disease. Strong evidence highlights complement activation as a key driver of the disease pathogenesis and its progression. In this regard, the emergence of new therapies targeting the complement system has further increased interest in specific biomarkers that can help in diagnosis, prognosis, and assessment of response to therapy in patients with IgAN. Although complement biomarkers show promising associations with disease severity and prognosis, most remain exploratory and lack adequate validation for routine clinical application. Further research should focus on standardization and prospective multicenter validation of putative biomarkers to facilitate a biomarker-driven approach to the use of complement inhibitors in IgAN. Therefore, this review summarizes a growing body of evidence on the role of complement-related biomarkers in IgAN and discusses their diagnostic and prognostic potential, as well as several limitations for implementation in clinical practice.<\/jats:p>","DOI":"10.3389\/fneph.2026.1918450","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:25:37Z","timestamp":1790249137000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement biomarkers in IgA nephropathy: current insights and clinical relevance"],"prefix":"10.3389","volume":"6","author":[{"given":"Altynay","family":"Balmukhanova","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Eng","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Tengku Ampuan Afzan","place":["Kuantan, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester","place":["Leicester, United Kingdom"]},{"name":"The John Walls Renal Unit, Leicester General Hospital","place":["Leicester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005020134","article-title":"IgA nephropathy","volume":"16","author":"Barratt","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejim.2024.02.015","article-title":"The complement system in the pathogenesis and progression of kidney diseases: What doesn\u2019t kill you makes you older","volume":"124","author":"Stea","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103705","DOI":"10.1016\/j.ekir.2025.11.029","article-title":"Complement-mediated kidney diseases: Role of alternative pathway in glomerular inflammation","volume":"11","author":"Barratt","year":"2026","journal-title":"Kidney Int Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.06.010","article-title":"Challenges in IgA nephropathy management: An era of complement inhibition","volume":"8","author":"Tesa\u0159","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: Design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600743","article-title":"Iptacopan in IgA nephropathy\u2014final 24-month data","volume":"395","author":"Barratt","year":"2026","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.kint.2025.11.017","article-title":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy","volume":"109","author":"Barbour","year":"2026","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S1974a","article-title":"IMAGINATION: A global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy: SA-PO885","volume":"34","author":"Cheng","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: A phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00117","article-title":"The origin and activities of IgA1-containing immune complexes in IgA nephropathy","volume":"7","author":"Knoppova","year":"2016","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000519973","article-title":"New insights into the pathogenesis and treatment strategies in IgA nephropathy","volume":"2","author":"Scionti","year":"2022","journal-title":"Glomerular Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: The lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.005","article-title":"Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins, and associated proteins","volume":"44","author":"Thiel","year":"2007","journal-title":"Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy073","article-title":"The lectin pathway in renal disease: Old concept and new insights","volume":"33","author":"Gaya da Costa","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad140","article-title":"The complement system in IgAN: Mechanistic context for therapeutic opportunities","volume":"38","author":"Duval","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599974","article-title":"Deposition of the membrane attack complex in healthy and diseased human kidneys","volume":"11","author":"Koopman","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01189-6","article-title":"IgA nephropathy and atypical hemolytic uremic syndrome: A case series and a literature review","volume":"35","author":"Manenti","year":"2022","journal-title":"J Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.03.416","article-title":"Microangiopathic lesions in IgA nephropathy: A cohort study","volume":"74","author":"Cai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0259-z","article-title":"Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis","volume":"32","author":"Chua","year":"2019","journal-title":"Mod Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233199","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy","volume":"15","author":"Neves","year":"2020","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","article-title":"Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis","volume":"23","author":"Suzuki","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: Biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan","year":"2024","journal-title":"biomark Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H\u2013related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.041","article-title":"Elevated factor H\u2013related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy","volume":"92","author":"Tortajada","year":"2017","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.02.023","article-title":"Circulating complement factor H\u2013related protein 5 levels contribute to development and progression of IgA nephropathy","volume":"94","author":"Zhu","year":"2018","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad163","article-title":"Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy","volume":"38","author":"\u0218tefan","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638309","article-title":"Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients","volume":"12","author":"Chiu","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-12-64","article-title":"Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function","volume":"12","author":"Onda","year":"2011","journal-title":"BMC Nephrol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.06.009","article-title":"Glomerular C4d deposition and kidney disease progression in IgA nephropathy: A systematic review and meta-analysis","volume":"3","author":"Jiang","year":"2021","journal-title":"Kidney Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac024","article-title":"The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: A cohort study","volume":"37","author":"Wang","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae001","article-title":"Association between urinary C4d levels and disease progression in IgA nephropathy","volume":"39","author":"Dong","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676919","article-title":"Complement activation is associated with crescents in IgA nephropathy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin\u2013associated serine protease-3 (MASP-3) and increased glomerular factor H\u2013related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.994408","article-title":"Clinical characteristics of IgA nephropathy associated with low complement 4 levels","volume":"37","author":"Zhu","year":"2015","journal-title":"Ren Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12882-019-1420-0","article-title":"Serum complement C4 is an important prognostic factor for IgA nephropathy: A retrospective study","volume":"20","author":"Bi","year":"2019","journal-title":"BMC Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030820","article-title":"Urinary C5b-9 as a prognostic marker in IgA nephropathy","volume":"11","author":"Yu","year":"2022","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae395","article-title":"Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity","volume":"18","author":"Nurmi","year":"2025","journal-title":"Clin Kidney J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2825(2000)14:5<220::AID-JCLA4>3.0.CO;2-2","article-title":"Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy","volume":"14","author":"Tomino","year":"2000","journal-title":"J Clin Lab Anal"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-65857-w","article-title":"Role of serum complement C3 and C4 on kidney outcomes in IgA nephropathy","volume":"14","author":"Tringali","year":"2024","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-8995-6","article-title":"Serum C3\/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study","volume":"66","author":"Pan","year":"2018","journal-title":"Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2026.2682078","article-title":"Clinical significance of serum complement levels and C3\/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications","volume":"48","author":"Ergun","year":"2026","journal-title":"Ren Fail"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-019-1331-0","article-title":"High serum IgA\/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria \u2264 1 g\/d: An observational cross-sectional study","volume":"20","author":"Gong","year":"2019","journal-title":"BMC Nephrol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-022-02244-7","article-title":"Correlation between IgAC3 ratio and oxford score in IgA nephropathy","volume":"26","author":"\u015eirali","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04104-7","article-title":"Serum IgA\/C3 ratio: a useful marker of disease activity in patients with IgA nephropathy","volume":"56","author":"Torikoshi","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-10578-x","article-title":"Serum IgA\/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy","volume":"15","author":"Swamy","year":"2025","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2020.1786400","article-title":"Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy","volume":"42","author":"Yang","year":"2020","journal-title":"Ren Fail"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.832998","article-title":"C4d as a screening tool and an independent predictor of clinical outcomes in lupus nephritis and IgA nephropathy","volume":"9","author":"Yang","year":"2022","journal-title":"Front Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108331","article-title":"Predictive value of mesangial C3 and C4d deposition in IgA nephropathy","volume":"211","author":"Nam","year":"2020","journal-title":"Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf200","article-title":"In situ assessment of glomerular C3\/C5 convertases indicates ongoing complement activation in IgA nephropathy","volume":"41","author":"Obrecht","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000536114","article-title":"Combined effects of the serum IgA\/C3 ratio and glomerular C3 staining on the renal outcome in adult immunoglobulin A nephropathy","volume":"49","author":"Yang","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13147","article-title":"C3-dependent effector functions of complement","volume":"313","author":"Zarantonello","year":"2023","journal-title":"Immunol Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90155-4","article-title":"Complement factor H and related proteins: an expanding family of complement-regulatory proteins","volume":"15","author":"Zipfel","year":"1994","journal-title":"Immunol Today"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.10071","article-title":"Significance of serum IgA levels and serum IgA\/C3 ratio in diagnostic analysis of patients with IgA nephropathy","volume":"17","author":"Maeda","year":"2003","journal-title":"J Clin Lab Anal"},{"key":"B72","unstructured":""},{"key":"B73","unstructured":""},{"key":"B74","unstructured":"Fabhalta"},{"key":"B75","unstructured":"ARTEMIS-IGAN: A randomized, double-blind, placebo-controlled phase 3 study of OMS721 in IgA nephropathy"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.444","article-title":"#1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy","volume":"39","author":"Trimarchi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2608684","article-title":"Retraction: Jayne DRW et\u00a0al. Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Rubin","year":"2026","journal-title":"N Engl J Med"},{"key":"B78","unstructured":"CDER proposes to withdraw approval of TAVNEOS"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117995","article-title":"Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1918450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:25:40Z","timestamp":1790249140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1918450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":80,"alternative-id":["10.3389\/fneph.2026.1918450"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1918450","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1918450"}}